Day One Biopharmaceuticals, Inc. (DAWN) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -14.15M | -5.8M | -24.81M | -59M | -30.01M | 50.75M | -49.13M | -49.73M | -41.37M | -37.06M | -42.43M | -25.98M |
| Operating CF Margin % | -26.34% | -14.59% | -73.16% | -191.79% | -102.74% | 54.13% | -599.72% | - | - | - | - | - |
| Operating CF Growth % | 52.85% | -111.44% | 49.51% | -18.64% | 27.47% | 236.93% | -15.78% | -91.38% | -17.17% | -59.66% | -42.45% | -20.51% |
| Net Income | -21.28M | -19.73M | -30.32M | -36M | -65.71M | 37.04M | -4.41M | -62.41M | -54.51M | -46.15M | -45.86M | -42.39M |
| Depreciation & Amortization | 886K | 885K | 886K | 819K | 759K | 746K | 408K | 116K | 103K | 99K | 92K | 89K |
| Stock-Based Compensation | 11.07M | 9.56M | 10.9M | 12.86M | 11.04M | 11.55M | 13.03M | 12.64M | 10.81M | 9.61M | 9.48M | 9.45M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41.58M | -45.79M | 4.22M | 0 |
| Other Non-Cash Items | -3.11M | -4.07M | -4M | -4.17M | -2.82M | 53.62M | -108.9M | -1.29M | -43.15M | 46.15M | -9.48M | -599K |
| Working Capital Changes | -1.72M | 7.55M | -2.27M | -32.51M | 26.73M | -52.21M | 50.74M | 1.22M | 3.8M | -975K | -879K | 7.47M |
| Change in Receivables | -10.04M | 2.97M | -1.61M | -4.18M | -5.18M | 441K | -9.14M | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 772K | -480K | -2.94M | -212K | -560K | -2.55M | -129K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -2.04M | 688K | 2.55M | -722K | 245K | -3.43M | 1.66M | 2.2M | -815K | -1.17M | -74K | 4.38M |
| Cash from Investing | 167.48M | 13.46M | 26.32M | -32.61M | -269.64M | -67.7M | 17.06M | 89.29M | 30.38M | 88.92M | 20.27M | -11.19M |
| Capital Expenditures | 0 | 0 | -3K | -317K | 15.68M | -724K | -17.13M | 0 | -8K | -3.04M | -149K | -26K |
| CapEx % of Revenue | 6.52% | - | 0.01% | 1.03% | 53.69% | 0.77% | 209.06% | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.99M | 3M | -20.42K | 11.17K |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -3.5M | -17.1M | -55M | 108M | 0 | 2.99M | -3M | 20.42K | -11.17K |
| Cash from Financing | 471K | 0 | 748K | 0 | 1.85M | 200.09M | 1.3M | 48K | 597K | 115K | 162.1M | 1.18M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 471K | 0 | 748K | 0 | 1.85M | 178.18M | 1.3M | 48K | 597K | 115K | 162.1M | 1.18M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 748K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 21.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 153.8M | 7.66M | 2.26M | -91.61M | -297.8M | 183.15M | -30.77M | 39.61M | -10.39M | 51.97M | 139.94M | -35.99M |
| Free Cash Flow | -17.65M | -5.8M | -21.31M | -62.81M | -31.43M | -4.97M | -66.25M | -49.73M | -41.38M | -40.1M | -42.58M | -26.01M |
| FCF Margin % | -32.85% | -14.59% | -62.84% | -204.2% | -107.6% | -5.3% | -808.78% | - | - | - | - | - |
| FCF Growth % | 43.84% | -16.78% | 67.84% | -26.31% | 24.05% | 87.61% | -55.6% | -91.18% | -17.19% | -72.73% | -42.92% | -20.54% |
| FCF per Share | -0.17 | -0.06 | -0.21 | -0.61 | -0.34 | -0.05 | -0.76 | -0.57 | -0.47 | -0.47 | -0.57 | -0.36 |
| FCF Conversion (FCF/Net Income) | 0.66x | 0.29x | 0.82x | 1.64x | 0.46x | 1.37x | 11.15x | 0.80x | 0.76x | 0.80x | 0.93x | 0.61x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1.01M | 883K | 0 | 0 | 0 | 0 | 0 | 0 |